TY - JOUR
T1 - Follow-up practice and healthcare utilisation of colorectal cancer survivors
AU - Qaderi, Seyed M.
AU - Ezendam, Nicole P. M.
AU - Verhoeven, Rob H. A.
AU - Custers, Jose A. E.
AU - de Wilt, Johannes H. W.
AU - Mols, Floortje
N1 - Funding Information: The present research was supported by a VENI Grant (#451‐10‐041) from the Netherlands Organization for Scientific Research (The Hague, The Netherlands) awarded to Floortje Mols. The funding body had no role in design, collection, analysis or interpretation of the data and in writing the manuscript. Funding Information: Rob H.A. Verhoeven received research grants from Roche and Bristol Myers‐Squib. The other authors have nothing to declare. Funding Information: The present research was supported by a VENI Grant (#451-10-041) from the Netherlands Organization for Scientific Research (The Hague, The Netherlands) awarded to Floortje Mols. The funding body had no role in design, collection, analysis or interpretation of the data and in writing the manuscript. We would like to thank all patients and their doctors for their participation in the study. Special thanks go to Dr. M. van Bommel, who was willing to function as an independent advisor and to answer questions of patients. In addition, we want to thank the following hospitals for their cooperation: Amphia Hospital, Breda; Bernhoven Hospital, Veghel and Oss; Catharina Hospital, Eindhoven; Elkerliek Hospital, Helmond; Jeroen Bosch Hospital, ?s-Hertogenbosch; Maxima Medical Center, Eindhoven and Veldhoven; Saint Anna Hospital, Geldrop; St. Elisabeth Hospital, Tilburg; TweeSteden Hospital, Tilburg and Waalwijk; and VieCuri Hospital, Venlo and Venray. Publisher Copyright: © 2021 The Authors. European Journal of Cancer Care published by John Wiley & Sons Ltd. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - Objective: To examine healthcare utilisation and adherence to colorectal cancer (CRC) follow-up guidelines. Methods: A total of 2450 out of 3025 stage I-III CRC survivors diagnosed between 2000 and 2009 completed the Hospital Anxiety and Depression Scale, SF-12, EORTC QLQ-CR38 and Fatigue Assessment Score questionnaires, in December 2010. Multivariable regression analyses were performed to identify predictors for increased follow-up care (>1 visit than recommended by guidelines). Results: In the first follow-up year, the average number of cancer-related visits to the general practitioner and medical specialist was 1.7 and 4.2, respectively. More than 80% of the CRC survivors was comfortable with their follow-up schedule, and 49–72% of them received follow-up according to the guidelines. Around 29–47% was followed more than recommended. Simultaneously, around 4–14% of the CRC survivors received less follow-up care than recommended. Survivors of stage III disease treated with chemotherapy received the most follow-up care. In addition, lower socio-economic status stoma and fatigue were associated with increased follow-up care. Conclusion: CRC survivors were predominantly followed according to national guidelines. Increased follow-up care is driven by advanced disease stage, chemotherapy, SES, stoma and fatigue. Future studies should investigate how increased follow-up care use can be reduced, while still addressing patients’ needs.
AB - Objective: To examine healthcare utilisation and adherence to colorectal cancer (CRC) follow-up guidelines. Methods: A total of 2450 out of 3025 stage I-III CRC survivors diagnosed between 2000 and 2009 completed the Hospital Anxiety and Depression Scale, SF-12, EORTC QLQ-CR38 and Fatigue Assessment Score questionnaires, in December 2010. Multivariable regression analyses were performed to identify predictors for increased follow-up care (>1 visit than recommended by guidelines). Results: In the first follow-up year, the average number of cancer-related visits to the general practitioner and medical specialist was 1.7 and 4.2, respectively. More than 80% of the CRC survivors was comfortable with their follow-up schedule, and 49–72% of them received follow-up according to the guidelines. Around 29–47% was followed more than recommended. Simultaneously, around 4–14% of the CRC survivors received less follow-up care than recommended. Survivors of stage III disease treated with chemotherapy received the most follow-up care. In addition, lower socio-economic status stoma and fatigue were associated with increased follow-up care. Conclusion: CRC survivors were predominantly followed according to national guidelines. Increased follow-up care is driven by advanced disease stage, chemotherapy, SES, stoma and fatigue. Future studies should investigate how increased follow-up care use can be reduced, while still addressing patients’ needs.
KW - Follow-up studies
KW - cancer survivorship
KW - colorectal cancer
KW - general practitioner
KW - healthcare use
UR - http://www.scopus.com/inward/record.url?scp=85107027235&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/ecc.13472
DO - https://doi.org/10.1111/ecc.13472
M3 - Article
C2 - 34081367
SN - 0961-5423
VL - 30
JO - European journal of cancer care
JF - European journal of cancer care
IS - 5
M1 - e13472
ER -